SHOCKWAVE MEDICAL INC (SWAV) Stock Fundamental Analysis
NASDAQ:SWAV - Nasdaq - US82489T1043 - Common Stock - Currency: USD
SWAV gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While SWAV has a great health rating, its profitability is only average at the moment. SWAV is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make SWAV a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
SWAV had positive earnings in the past year.
SWAV had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: SWAV reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: SWAV reported negative operating cash flow in multiple years.
1.2 Ratios
SWAV has a better Return On Assets (9.95%) than 93.23% of its industry peers.
With an excellent Return On Equity value of 21.76%, SWAV belongs to the best of the industry, outperforming 95.31% of the companies in the same industry.
SWAV has a Return On Invested Capital of 8.81%. This is amongst the best in the industry. SWAV outperforms 88.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROIC | 8.81% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SWAV has a better Profit Margin (20.76%) than 94.79% of its industry peers.
With an excellent Operating Margin value of 20.52%, SWAV belongs to the best of the industry, outperforming 94.27% of the companies in the same industry.
With an excellent Gross Margin value of 86.99%, SWAV belongs to the best of the industry, outperforming 96.35% of the companies in the same industry.
SWAV's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SWAV is destroying value.
The number of shares outstanding for SWAV has been increased compared to 1 year ago.
SWAV has more shares outstanding than it did 5 years ago.
SWAV has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 10.26 indicates that SWAV is not in any danger for bankruptcy at the moment.
SWAV has a better Altman-Z score (10.26) than 86.98% of its industry peers.
SWAV has a debt to FCF ratio of 4.41. This is a neutral value as SWAV would need 4.41 years to pay back of all of its debts.
SWAV has a Debt to FCF ratio of 4.41. This is amongst the best in the industry. SWAV outperforms 82.81% of its industry peers.
A Debt/Equity ratio of 0.97 indicates that SWAV is somewhat dependend on debt financing.
SWAV has a worse Debt to Equity ratio (0.97) than 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 10.26 |
ROIC/WACC0.94
WACC9.36%
2.3 Liquidity
A Current Ratio of 13.81 indicates that SWAV has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.81, SWAV belongs to the top of the industry, outperforming 97.92% of the companies in the same industry.
A Quick Ratio of 12.61 indicates that SWAV has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 12.61, SWAV belongs to the top of the industry, outperforming 97.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.34% over the past year.
Looking at the last year, SWAV shows a very strong growth in Revenue. The Revenue has grown by 41.44%.
The Revenue has been growing by 126.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
3.2 Future
SWAV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.56% yearly.
SWAV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.10% yearly.
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 78.21 indicates a quite expensive valuation of SWAV.
SWAV's Price/Earnings ratio is a bit cheaper when compared to the industry. SWAV is cheaper than 67.19% of the companies in the same industry.
When comparing the Price/Earnings ratio of SWAV to the average of the S&P500 Index (26.03), we can say SWAV is valued expensively.
Based on the Price/Forward Earnings ratio of 53.09, the valuation of SWAV can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 68.75% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.94. SWAV is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SWAV is valued a bit cheaper than the industry average as 67.19% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, SWAV is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 75.65 | ||
| EV/EBITDA | 66.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SWAV does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of SWAV may justify a higher PE ratio.
SWAV's earnings are expected to grow with 24.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y24.15%
5. Dividend
5.1 Amount
No dividends for SWAV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
334.75
-0.08 (-0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners10.85%
Inst Owner Change-99.96%
Ins Owners5.23%
Ins Owner Change0%
Market Cap12.57B
Analysts53.75
Price Target330.75 (-1.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.32%
Min EPS beat(2)27.98%
Max EPS beat(2)44.66%
EPS beat(4)3
Avg EPS beat(4)18.35%
Min EPS beat(4)-12.88%
Max EPS beat(4)44.66%
EPS beat(8)7
Avg EPS beat(8)24.97%
EPS beat(12)11
Avg EPS beat(12)73.56%
EPS beat(16)13
Avg EPS beat(16)54.46%
Revenue beat(2)1
Avg Revenue beat(2)1.53%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)3.29%
Revenue beat(4)2
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-1.27%
Max Revenue beat(4)3.29%
Revenue beat(8)5
Avg Revenue beat(8)2.94%
Revenue beat(12)9
Avg Revenue beat(12)5.4%
Revenue beat(16)13
Avg Revenue beat(16)8.23%
PT rev (1m)2.57%
PT rev (3m)25.91%
EPS NQ rev (1m)-2.66%
EPS NQ rev (3m)-2.74%
EPS NY rev (1m)6.44%
EPS NY rev (3m)16.18%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 | ||
| P/S | 15.95 | ||
| P/FCF | 75.65 | ||
| P/OCF | 63.5 | ||
| P/B | 16.72 | ||
| P/tB | 20.26 | ||
| EV/EBITDA | 66.43 |
EPS(TTM)4.28
EY1.28%
EPS(NY)6.31
Fwd EY1.88%
FCF(TTM)4.42
FCFY1.32%
OCF(TTM)5.27
OCFY1.57%
SpS20.99
BVpS20.03
TBVpS16.52
PEG (NY)2.17
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROCE | 10.42% | ||
| ROIC | 8.81% | ||
| ROICexc | 26.17% | ||
| ROICexgc | 34.98% | ||
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% | ||
| FCFM | 21.08% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
F-Score5
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 4.22 | ||
| Cap/Depr | 270.11% | ||
| Cap/Sales | 4.03% | ||
| Interest Coverage | 30.21 | ||
| Cash Conversion | 114.09% | ||
| Profit Quality | 101.56% | ||
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 | ||
| Altman-Z | 10.26 |
F-Score5
WACC9.36%
ROIC/WACC0.94
Cap/Depr(3y)384.02%
Cap/Depr(5y)409.93%
Cap/Sales(3y)4.85%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
EBIT growth 1Y8.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.79%
EBIT Next 3Y41.48%
EBIT Next 5Y38.45%
FCF growth 1Y635%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y478.63%
OCF growth 3YN/A
OCF growth 5YN/A